rs11466750 — TSLP 3'UTR Splice Variant

3'UTR variant in TSLP that acts as an eQTL driving higher TSLP mRNA expression in nasal epithelium; the A allele is a risk factor for asthma, atopic dermatitis, and elevated IgE, and co-defines the high-risk genotype together with rs2289277

See your personal result for TSLP

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

TSLP 3'UTR — The Expression Amplifier That Turns Up Allergic Alarm Volume

Thymic stromal lymphopoietin (TSLP)11 Thymic stromal lymphopoietin (TSLP)
An epithelial-derived alarmin cytokine that acts as the master initiator of allergic immune responses at barrier surfaces including skin, airways, and gut does not just have one genetic dial — it has several. The rs11466750 variant sits in the 3' untranslated region (3'UTR) of exon 4, downstream of the coding sequence, and operates as an expression quantitative trait locus (eQTL)22 expression quantitative trait locus (eQTL)
A genetic variant that controls how much of a nearby gene's mRNA is produced, without changing the protein sequence itself. While the protein produced from each transcript is identical, the A allele influences mRNA stability and translational efficiency — the result is more TSLP protein at barrier surfaces when the epithelium is triggered.

The variant is on chromosome 5q22.1, within the same TSLP gene that also harbours the well-studied upstream regulatory variant rs1837253. Unlike rs1837253, which modulates the inducibility of TSLP transcription, rs11466750 acts downstream — at the mRNA level — to alter how efficiently the transcript is processed and translated. Together with the intronic eQTL rs2289277, these two variants define a high-risk genotype combination that jointly predicts both elevated nasal-epithelial TSLP expression and childhood asthma risk.

The Mechanism

The 3'UTR of a gene contains binding sites for microRNAs and RNA-binding proteins that govern mRNA half-life, polyadenylation efficiency, and ribosomal access. The c.*1122G>A change33 c.*1122G>A change (HGVS: NM_033035.5:c.*1122G>A) falls 1,122 nucleotides after the TSLP stop codon, placing it within the long-form TSLP 3'UTR regulatory zone. The A allele is predicted to alter local RNA secondary structure and regulatory element accessibility, shifting the balance toward increased mRNA stability and higher steady-state TSLP levels in stimulated epithelial cells.

Functionally, the A allele at rs11466750 behaves as a gain-of-function eQTL: carriers of at least one A allele show significantly higher long-form TSLP mRNA in nasal epithelial cells44 significantly higher long-form TSLP mRNA in nasal epithelial cells compared to GG homozygotes (p=0.031). This elevated expression drives the downstream allergic cascade — dendritic cell activation, OX40L upregulation, Th2 polarisation, IgE production, and mast cell priming — all the hallmarks of atopic disease.

The Evidence

The most direct evidence comes from a Cincinnati children's cohort study published in the Journal of Allergy and Clinical Immunology (2022)55 Journal of Allergy and Clinical Immunology (2022), which assessed 51 participants aged 6–18 years. Individuals carrying at least one copy of the rs11466750 A allele (in combination with rs2289277 CC) showed markedly elevated nasal epithelial TSLP mRNA. The combination of risk genotype and high TSLP expression was strikingly predictive: 90% asthma prevalence66 90% asthma prevalence in carriers with top-tertile expression vs 40% in non-carriers with low expression (p=0.024). The adjusted OR for combined asthma and atopic dermatitis diagnosis was 3.33 (p=0.04) for carriers vs non-carriers.

Earlier work by Gao et al. (2010)77 Gao et al. (2010) in a predominantly European American cohort with atopic dermatitis found rs11466750 significantly associated with total serum IgE concentrations (p=0.048) — a biomarker of the systemic Th2 skewing that underlies allergic sensitisation. In a Korean cohort, rs11466750 clusters in haplotype block 288 rs11466750 clusters in haplotype block 2 with the adjacent variant rs11466749 (D'=1.0 in LD), and Korean patients without the full complement of nine TSLP protective variants had an 8.14-fold higher risk of progressing from atopic dermatitis to full atopic march (asthma plus allergic rhinitis).

A Turkish pediatric cohort of 506 asthmatic children and 157 controls99 506 asthmatic children and 157 controls confirmed that the exon 4 region (where rs11466750 sits) contains variants predictive of asthma when combined with atopy status. Small Caucasian pediatric studies have reported no AA homozygotes at all in their samples, consistent with the low global frequency of the AA genotype (~3%) and the rarity of homozygous risk individuals outside of African-ancestry populations.

TSLP itself is now validated as a therapeutic target: tezepelumab (Tezspire) — an anti-TSLP monoclonal antibody — is FDA-approved for severe asthma, directly neutralising the protein that rs11466750 and its co-variants overproduce.

Practical Implications

For AG and AA carriers, the elevated TSLP expression from this variant amplifies epithelial alarm signals at barrier surfaces. Managing triggers that stimulate TSLP release — allergens, irritants, viral infections — directly addresses the genotype's mechanism. If asthma is severe or difficult to control, the TSLP pathway is the biological driver, and anti-TSLP biologics specifically target the protein this variant overproduces.

The variant also has cross-tissue relevance: the 3'UTR eQTL effect has been observed in both lung and skin, meaning rs11466750 A carriers may have elevated TSLP not just in the airways but also at the skin barrier — contributing to the atopic triad pattern where eczema, rhinitis, and asthma co-occur.

Interactions

rs11466750 does not act alone. Its primary functional partner is rs22892771010 rs2289277
An intronic TSLP variant that co-defines the high-risk genotype with rs11466750; located in intron 2 of long-form TSLP and the short-form promoter region — carriers of both risk genotypes (rs2289277 CC + rs11466750 A≥1) show the strongest TSLP expression and asthma association. The upstream regulatory variant rs18372531111 rs1837253
The most studied TSLP SNP; the T allele reduces TSLP production 2.5-fold and protects against asthma and allergic rhinitis operates at the transcriptional level, while rs11466750 acts at the post-transcriptional (3'UTR) level — together they represent two independent points of control over TSLP output. Carriers who have both the rs1837253 CC risk genotype and rs11466750 AA are exposed to elevated TSLP from both transcriptional and translational directions.

Genotype Interpretations

What each possible genotype means for this variant.

GG Standard TSLP Expression Normal

Reference genotype with baseline TSLP 3'UTR regulation and normal allergic risk

You carry two copies of the G reference allele at this 3'UTR position. The G allele is the predominant form worldwide, present in approximately 69% of people globally. Your TSLP mRNA 3'UTR regulation is at the population-typical level — this genotype does not amplify TSLP expression through post-transcriptional effects. Your allergic risk is not elevated by this specific variant.

AG Elevated TSLP Expression Intermediate

One copy of the 3'UTR risk allele linked to moderately elevated nasal TSLP expression

The AG genotype places you in the group that the Murrison et al. (2022) JACI study defined as "risk genotype carriers." In that cohort, carriers with top-tertile TSLP nasal expression had 90% asthma prevalence, compared to 40% in non-carriers with low expression (p=0.024). The heterozygous state provides partial eQTL effect — one A allele shifts mRNA stability toward higher output without reaching the level of the AA homozygote.

The 3'UTR effect is tissue-relevant in both lung and skin. If you have atopic dermatitis, this variant may contribute to elevated cutaneous TSLP, which perpetuates the skin-to-airway sensitisation sequence of the atopic march.

AA High TSLP Expression High Risk

Homozygous risk genotype with strongest post-transcriptional TSLP amplification and highest atopic disease risk

The AA homozygote represents the full eQTL dose at the 3'UTR locus. Two copies of the A allele create the maximal shift in TSLP mRNA stability — more transcripts, more protein, stronger Th2 polarisation of dendritic cells, greater IgE production, and more robust mast cell and basophil priming at barrier surfaces. Serum IgE studies in European American AD cohorts showed rs11466750 association with total IgE (Gao et al. 2010); the homozygous AA state likely represents the strongest genotypic effect.

In Korean cohorts (Seo et al. 2018), the haplotype block containing rs11466750 (with rs11466749) was validated in atopic dermatitis patients, though individual SNP analysis showed modest ORs. The cumulative picture across studies — eQTL functional data, IgE associations, and atopic march risk — consistently places AA homozygotes at the high end of TSLP-driven atopic risk.

Tezepelumab (Tezspire), an FDA-approved anti-TSLP biologic for severe asthma, directly neutralises the TSLP protein this variant overproduces. AA carriers with severe or difficult-to-control asthma represent the biological target population for this drug class.